1.
J Mater Chem B
; 4(4): 585-588, 2016 Jan 28.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32262940
RESUMEN
Nanoparticles of a mesoporous iron(iii) trimesate MIL-100 nanocarrier encapsulating high amounts of the challenging antineoplastic busulfan were administered to rats and compared with the commercial Busilvex®. Large differences in serum concentration of both busulfan and trimesate revealed the great impact of drug encapsulation both on the drug and on nanoparticle pharmacokinetics during the first 24 h of administration.